OKYO-0101 is under clinical development by OKYO Pharma and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OKYO-0101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OKYO-0101 overview

OKYO-0101 is under development for the treatment of dry eye, uveitis, allergic conjunctivitis and neuropathic corneal pain. The drug candidate comprises of 9-amino acid coupled with chemerin peptide. It is administered by ophthalmic route. It is developed based on membrane-tethered ligand technology and membrane-anchored-peptide (MAP) technology. It acts by targeting ChemR23 G-protein coupled receptor.

OKYO Pharma overview

OKYO Pharma, formerly West African Mineral Corporation, is a biopharmaceutical company. It develops therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. The company focuses on the treatment of dry eye disease, non-infectious anterior uveitis, allergic conjunctivitis, chronic pain and ocular pain. Its pipeline products include OK-101 for the treatment of inflammation and neuropathic pain in mice and OK-201 for the treatment of ocular pain and chronic pain. The company operates in New York, the US and London. OKYO Pharma is headquartered in London, Greater London, the UK.

For a complete picture of OKYO-0101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.